These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 7353382

  • 1. Skeletal response to treatment with 1,25-dihydroxyvitamin D in renal failure.
    Sherrard DJ, Coburn JW, Brickman AS, Singer FR, Maloney N.
    Contrib Nephrol; 1980; 18():92-7. PubMed ID: 7353382
    [No Abstract] [Full Text] [Related]

  • 2. Clinical effects of 1,25-dihydroxyvitamin D3 in uremic patients with overt osteodystrophy.
    Brickman AS, Coburn JW, Sherrard DJ, Wong EG, Norman AW, Singer FR.
    Contrib Nephrol; 1980; 18():29-41. PubMed ID: 7353378
    [No Abstract] [Full Text] [Related]

  • 3. [Treatment of uremic osteopathy. Effects of vitamin D metabolites and vitamin D analogs in chronic uremia and experimental renal insufficiency].
    von Herrath D, Kraft D, Schaefer K, Krempien B.
    MMW Munch Med Wochenschr; 1974 Sep 13; 116(37):1573-8. PubMed ID: 4374654
    [No Abstract] [Full Text] [Related]

  • 4. The effects of calciferol and its metabolites on patients with chronic renal failure. II. Calcitriol, 1 alpha-hydroxyvitamin D3, and 24,25-dihydroxyvitamin D3.
    Voigts AL, Felsenfeld AJ, Llach F.
    Arch Intern Med; 1983 Jun 13; 143(6):1205-11. PubMed ID: 6344827
    [Abstract] [Full Text] [Related]

  • 5. Do parathyroid hormone and 1,25-dithydroxyvitamin D modulate bone formation in uremia?
    Teitelbaum SL, Bergfeld MA, Freitag J, Hruska KA, Slatopolsky E.
    J Clin Endocrinol Metab; 1980 Aug 13; 51(2):247-51. PubMed ID: 6893204
    [No Abstract] [Full Text] [Related]

  • 6. Experience with 1,25-dihydroxycholecalciferol therapy in undergoing hemodialysis patients with progressive vitamin D2-treated osteodystrophy.
    Prior JC, Cameron EC, Ballon HS, Lirenman DS, Moriarty MV, Price JD.
    Am J Med; 1979 Oct 13; 67(4):583-9. PubMed ID: 386792
    [Abstract] [Full Text] [Related]

  • 7. An evaluation of 1 alpha-hydroxy-and 1,25-dihydroxyvitamin D3 in the treatment of renal bone disease.
    Kanis JA, Russell RG, Cundy T, Earnshaw M, Woods CG, Smith R, Heynen G.
    Contrib Nephrol; 1980 Oct 13; 18():12-28. PubMed ID: 7353370
    [Abstract] [Full Text] [Related]

  • 8. The use of metabolites and analogues of vitamin D in prospective renal transplant recipients.
    Cundy T, Kanis JA, Fraher L, Clemens TL, O'Riordan JL.
    Clin Nephrol; 1981 May 13; 15(5):240-5. PubMed ID: 7018772
    [No Abstract] [Full Text] [Related]

  • 9. The action of 1,25 (OH)2D3 on turnover kinetic, remodelling surfaces and structure of trabecular bone in chronic renal failure.
    Delling G, Lühmann H, Bulla M, Fuchs C, Henning HV, Jansen JL, Kohnle W, Schulz W.
    Contrib Nephrol; 1980 May 13; 18():105-21. PubMed ID: 7353369
    [Abstract] [Full Text] [Related]

  • 10. Long-term effects of small doses of 1,25-dihydroxycholecalciferol in renal osteodystrophy.
    Ahmed KY, Varghese Z, Wills MR, Meinhard EA, Moorhead JF.
    Lancet; 1978 Mar 25; 1(8065):629-32. PubMed ID: 76168
    [Abstract] [Full Text] [Related]

  • 11. Histopathology of renal osteodystrophy with particular reference to the effects of 1alpha-hydroxyvitamin D3 in patients treated by long-term haemodialysis.
    Ellis HA, Pierides AM, Feest TG, Ward MK, Kerr DN.
    Clin Endocrinol (Oxf); 1977 Dec 25; 7 Suppl():31s-38s. PubMed ID: 606422
    [Abstract] [Full Text] [Related]

  • 12. The role of vitamin D in renal bone disease.
    Stanbury SW.
    Clin Endocrinol (Oxf); 1977 Dec 25; 7 Suppl():25s-30s. PubMed ID: 342146
    [No Abstract] [Full Text] [Related]

  • 13. Editorial: Azotaemic renal osteodystrophy.
    Med J Aust; 1974 Jun 01; 1(22):864-5. PubMed ID: 4851493
    [No Abstract] [Full Text] [Related]

  • 14. [Bone changes in chronic renal insufficiency].
    Ritz E, Krempien B, Prager P, Bommer J, Mehls O, Andrassy K.
    Med Klin; 1975 Jun 27; 70(26):1112-24. PubMed ID: 772387
    [No Abstract] [Full Text] [Related]

  • 15. Treatment of renal bone disease.
    Lancet; 1975 Jun 27; 2(8156-8157):1339-40. PubMed ID: 92678
    [No Abstract] [Full Text] [Related]

  • 16. A skeletal mineralizing defect in dialysis patients: a syndrome resembling osteomalacia but unrelated to viatamin D.
    Coburn JW, Sherrard DJ, Brickman AS, Wong EG, Norman AW, Singer FR.
    Contrib Nephrol; 1980 Jun 27; 18():172-83. PubMed ID: 7353374
    [No Abstract] [Full Text] [Related]

  • 17. 'One-alpha'.
    Lancet; 1978 May 06; 1(8071):973-4. PubMed ID: 76898
    [No Abstract] [Full Text] [Related]

  • 18. Treatment of renal osteodystrophy with calciferol (vitamin D) and related steroids.
    Brickman AS, Norman AW.
    Kidney Int; 1973 Aug 06; 4(2):161-7. PubMed ID: 4364427
    [No Abstract] [Full Text] [Related]

  • 19. Biochemical and histological effects of 1,25 dihydroxycholecalciferol (1,25-DHCC) in the osteomalacia of chronic and failure.
    Eastwood JB, Phillips ME, de Wardener HE, Bordier J, Marie P, Arnaud CD, Norman AW.
    J Urol Nephrol (Paris); 1974 Dec 06; 80(12):984-5. PubMed ID: 4617780
    [No Abstract] [Full Text] [Related]

  • 20. [Vitamin D and renal failure (author's transl)].
    Fuss M, Corvilain J.
    Rev Med Brux; 1981 Apr 06; 2(4):441-5. PubMed ID: 7291796
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.